NCT01403480已完成不适用
Rates of Positive BCCs in Re-excisions
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 600
研究概览
简要总结
Basal Cell Carcinoma (BCC) is the most common malignant growth in the world. Treatment is primarily surgical with the goal of excising the growth in its entirety. When pathology results show that this has not been achieved, a re-excision is routinely performed. This study examines retrospectively the percentage of re-excisions of BCC that actually proved to be positive (exhibited growth) among those re-excisions performed at Rambam Healthcare Campus and Zvulun Community Medical Center during the years 2008-10.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •All patients that underwent an incomplete BCC excision during the years 2008-2010.
排除标准
- •Patients that underwent an incomplete BCC excision and were subsequently referred to undergo a MOHS procedure.
研究者
相似试验
已完成
2 期
Study Evaluating the Efficacy and Safety of 0.05% Ingenol Mebutate (Picato® 500) in the Treatment of Basal Cell CarcinomaCarcinomaNCT03546166Centre Hospitalier Universitaire de Nice24
已完成
不适用
Basal Cell Carcinoma Recurrence After Mohs SurgeryBasal Cell CarcinomaNCT00882791Northwestern University115
暂停
不适用
Curettage Versus Excision in Nodular and Superficial Basal Cell CarcinomasCarcinoma, Basal CellNCT00515970University Hospital Tuebingen400
Unknown
3 期
Surgery Versus Combined Treatment With Curettage and Imiquimod for Nodular Basal Cell CarcinomaNodular Basal Cell CarcinomaNCT02242929Maastricht University Medical Center145
已完成
3 期
Aldara for the Treatment of Large and/or Multiple sBCCCarcinoma, Basal CellNCT00189280MEDA Pharma GmbH & Co. KG111